WEDNESDAY, Sept. 28, 2022 (HealthDay) — Japanese drugmaker Eisai on Wednesday said its experimental drug lecanemab helped slow thinking declines among people in the early stages of Alzheimer’s disease. The findings from a phase 3 clinical trial have yet to be peer-reviewed in any medical journal. But according to aContinue Reading

MONDAY, Sept. 26, 2022 (HealthDay News) — People who work in manufacturing, welding and chemical operations and are exposed to hazardous chemicals may face a higher risk of developing amyotrophic lateral sclerosis (ALS), a new study found. “This study shows that certain occupational settings and exposures increase one’s chances ofContinue Reading

FRIDAY, Sept. 23, 2022 (HealthDay News) — People with a rare genetic form of ALS may benefit from extended use of an investigational drug, a new study shows. The medication, tofersen, benefited patients with mutations of the gene SOD1. These mutations create a misfolded version of a protein, which leadsContinue Reading

THURSDAY, Sept. 22, 2022 (HealthDay News) — No one likes nightmares, but having persistently bad dreams may also signal impending dementia, new British research suggests. In the study, people aged 35 to 64 who had bad dreams weekly were four times more likely to have cognitive decline over the followingContinue Reading

FRIDAY, Sept. 16, 2022 (HealthDay News) — COVID-19 infection may significantly boost an older person’s risk of developing Alzheimer’s disease, a new, large-scale study suggests. People 65 and older who contracted COVID were nearly 70% more likely overall to be diagnosed with Alzheimer’s within a year of their infection, researchersContinue Reading